Properties of chemotherapeutic agents:
Spectrum of Activity:
- Broad-spectrum: Effective against a wide range of microorganisms.
- Narrow-spectrum: Effective against a limited number of microorganisms.
2. Mechanism of Action:
- Cell wall synthesis inhibition: Disrupting the formation of the microbial cell wall, leading to cell lysis.
- Protein synthesis inhibition: Interfering with the microbial protein production, halting growth.
- DNA/RNA synthesis inhibition: Blocking the replication or transcription of microbial genetic material.
- Metabolic pathway disruption: Interfering with essential metabolic processes in the microorganism.
3. Potency:
- Minimum Inhibitory Concentration (MIC): The lowest concentration of a chemotherapeutic agent that inhibits the growth of a microorganism.
- Minimum Bactericidal Concentration (MBC): The lowest concentration of a chemotherapeutic agent that kills the microorganism.
4. Pharmacokinetics:
- Absorption: How well the chemotherapeutic agent is absorbed into the body.
- Distribution: How the chemotherapeutic agent is distributed throughout the body.
- Metabolism: How the chemotherapeutic agent is broken down by the body.
- Excretion: How the chemotherapeutic agent is eliminated from the body.
5. Toxicity:
- Selective toxicity: The ability of a chemotherapeutic agent to target microorganisms without harming the host.
- Adverse effects: Unwanted side effects that may occur with the use of a chemotherapeutic agent.
6. Resistance:
- Development of resistance: Microorganisms can develop resistance to chemotherapeutic agents, making them less effective.
- Mechanisms of resistance: Microorganisms can develop various mechanisms to evade the effects of chemotherapeutic agents.
7. Stability:
- Chemical stability: How stable the chemotherapeutic agent is over time and under different conditions.
- Storage conditions: Proper storage conditions are essential to maintain the stability and effectiveness of chemotherapeutic agents.
Antibacterial mode of action:
Cell wall synthesis inhibition:
- Antibiotics in this class interfere with the synthesis of peptidoglycan, a crucial component of the bacterial cell wall.
- This weakens the cell wall, leading to bacterial lysis and death.
Protein synthesis inhibition:
- Antibiotics in this class target bacterial ribosomes, the protein-making machinery, without affecting human ribosomes.
- They disrupt different stages of protein synthesis, preventing bacteria from producing essential proteins.
DNA/RNA synthesis inhibition:
- Antibiotics in this class interfere with various processes involved in DNA/RNA synthesis.
- Some block the enzymes responsible for DNA replication or RNA transcription, while others damage the DNA itself.
Metabolic pathway disruption:
- Antibiotics in this class target specific enzymes involved in these pathways, disrupting essential metabolic processes.
- For example, sulfonamides interfere with folic acid synthesis, which is crucial for bacterial growth.
Cell membrane disruption:
- Antibiotics in this class disrupt the structure or function of the bacterial cell membrane.
- This leads to leakage of cellular contents and bacterial death.
Antifungal mode of action:
Cell wall synthesis inhibition:
- Antibiotics in this class interfere with the synthesis of peptidoglycan, a crucial component of the bacterial cell wall.
- This weakens the cell wall, leading to bacterial lysis and death.
Ergosterol synthesis inhibition:
- Antifungal drugs in this class interfere with the enzymes involved in ergosterol synthesis.
- This depletes ergosterol in the fungal cell membrane, leading to cell damage and death
Cell wall synthesis inhibition:
- Antifungal drugs in this class target the enzymes responsible for synthesizing these polysaccharides, such as glucan synthase.
- This weakens the fungal cell wall, making it more susceptible to damage and lysis.
Nucleic acid synthesis inhibition:
- Fungal cells need to replicate their DNA and transcribe it into RNA to grow and divide.
- Antifungal drugs in this class interfere with various processes involved in DNA/RNA synthesis in fungal cells.
Antiviral mode of action:
Attachment and entry inhibition:
- Viruses initiate infection by attaching to specific receptors on the surface of host cells.
- Antiviral drugs in this class block these receptors, preventing the virus from attaching and entering the cell.
Uncoating inhibition:
- Once inside the cell, the virus needs to shed its outer coat (uncoating) to release its genetic material.
- Antiviral drugs in this class interfere with this uncoating process, preventing the virus from replicating.
Nucleic acid synthesis inhibition:
- Antiviral drugs in this class target the enzymes responsible for viral nucleic acid synthesis, such as viral polymerases or reverse transcriptase.
- This prevents the virus from replicating its genetic material and halts further viral production.
Protein synthesis inhibition:
- Viruses need to produce viral proteins to assemble new viral particles.
- Antiviral drugs in this class interfere with the synthesis of specific viral proteins, preventing the virus from multiplying.
Assembly and release inhibition:
- After viral components are produced, they need to be assembled into new viral particles and released from the host cell to infect other cells.
- Antiviral drugs in this class interfere with the assembly or release of viral particles, preventing the spread of infection.
Antiprotozoal mode of action:
Interference with nucleic acid synthesis:
- Protozoa need to replicate their DNA and transcribe it into RNA to grow and divide.
- Antiprotozoal drugs in this class interfere with various processes involved in DNA/RNA synthesis in protozoan cells.
Disruption of metabolic pathways:
- Protozoa have unique metabolic pathways that are essential for their survival.
- Antiprotozoal drugs in this class target specific enzymes involved in these pathways, disrupting essential metabolic processes.
Interference with protein synthesis:
- Protozoa need to produce proteins to survive and multiply.
- Antiprotozoal drugs in this class target protozoan ribosomes, the protein-making machinery, without affecting human ribosomes.
Disruption of cell membrane function:
- The protozoan cell membrane acts as a barrier, regulating what enters and exits the cell.
- Antiprotozoal drugs in this class disrupt the structure or function of the protozoan cell membrane.
Inhibition of parasite-specific enzymes:
- Some antiprotozoal drugs target enzymes that are unique to protozoa and not found in humans.
- This allows for selective toxicity, killing the protozoa without harming the host.
Comments
Post a Comment